Latest Insights - page 10 | BiopharmaTrend

In a $66M Deal, Insilico Medicine and Hygtia Will Develop an AI-Designed Brain-Penetrant NLRP3 Inhibitor for CNS Diseases

Insilico Medicine and Hygtia Therapeutics have entered a global co-development and licensing agreement for ISM8969, an orally available, blood-brain barrier–penetrant NLRP3 inhibitor intended for central nervous system (CNS) disorders such …

Continue ›››

A 24-Hour Snapshot of AI Drug Discovery Across Pharma, Biotech, and Research

London-based Isomorphic Labs broke the news with yet another pharmaceutical partnership, announcing a new research collaboration with Johnson & Johnson’s Janssen Biotech unit aimed at AI-driven drug discovery across multiple …

Continue ›››

Isomorphic Labs and Johnson & Johnson Partner on AI-Driven, Multi-Modality Drug Discovery

Isomorphic Labs has announced a cross-modality research collaboration with Johnson & Johnson, aimed at integrating its AI-based drug design engine with Johnson & Johnson’s experimental and clinical development infrastructure. The …

Continue ›››

Scribe to Start First Human Trial of One-Time CRISPR Therapy for Cardiovascular Disease

Scribe Therapeutics is preparing to enter the clinic in mid-2026 with Phase 1 studies of STX-1150, a one-time CRISPR-based therapy designed to silence genes linked to high cholesterol without cutting …

Continue ›››

OpenAI Backs Ultrasound-Based Brain-Computer Interface Startup With $252M Seed Round

Merge Labs has emerged from stealth with $252 million in funding to develop non-implantable brain–computer interfaces that use ultrasound and molecular approaches rather than electrodes. The company is cofounded by …

Continue ›››

Insilico Deploys its Chemistry Foundation Model on Microsoft Discovery Platform

Insilico Medicine reported the deployment of its Nach01 multimodal foundation model on Microsoft Discovery, Microsoft’s Azure-based platform for AI-driven research and development. The demonstration illustrates how third-party foundation models can …

Continue ›››

Novo Nordisk Foundation Commits €736M to Scale European Life Sciences

The Novo Nordisk Foundation has committed up to €736 million (~$856 million) to Copenhagen-based BioInnovation Institute in a nine-year funding program aimed at expanding early-stage life sciences and deep tech …

Continue ›››

BMS Taps Immunai’s AI Immune Atlas To Decode Clinical Trial Responses

Immunai has entered a strategic collaboration with Bristol Myers Squibb (BMS) to apply its AI-powered operating system, AMICA-OS, in support of BMS’s clinical development programs. The partnership focuses on leveraging …

Continue ›››

2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic

Forward signals for 2026—from >$1.3B in tracked financings led by Neuralink’s $650M round to a shoebox-sized biocomputer, driven device control, speech restoration, and early clinical proof points. As we step …

Continue ›››

Converge Bio Raises $25M for Generative AI Systems in Antibody and Protein Design

Converge Bio, a Boston- and Tel Aviv-based startup developing generative AI systems for drug discovery, has raised a $25 million oversubscribed Series A round led by Bessemer Venture Partners, with …

Continue ›››

Google Updates Open Medical AI Suite With New Imaging and Speech Models, Launches $100K Developer Hackathon

Google has released updates to its open-source medical AI suite with MedGemma 1.5 4B and a new speech-to-text model, MedASR, and introduced the MedGemma Impact Challenge, a hackathon hosted on …

Continue ›››

Tahoe, Arc Institute, and Biohub Collaborate to Release Largest Open Dataset for Virtual Cell Modeling

Tahoe Therapeutics (formerly Vevo), Arc Institute, and CZI’s Biohub have announced a joint initiative to generate what is reportedly the largest and most perturbation-rich single-cell dataset available for virtual cell …

Continue ›››